Product pipeline
Intercell’s strategy is to keep a broad but focused product portfolio. Our goal is to launch a continuous flow of products, and we are committed to moving ahead. We strive for a balance between in-house manufacturing and strategic partnerships to speed up vaccine development.
Vaccines on the market
| Products | Vaccine/ Type |
Status | Expected Milestones |
Strategic Partner |
|
|---|---|---|---|---|---|
| 1 | Japanese Encephalitis vaccine | Prophylactic | Approved U.S., Australien, Europa, Canada | Country approvals in various territories Expansion of label (children) |
Novartis / CSL / Biological Ltd. |
Vaccines in clinical phases
| Product Candidate |
Vaccine Type |
Status/ Phase |
Expected Milestones |
Strategic Partner |
|
|---|---|---|---|---|---|
| 2 | Travelers' Diarrhea vaccine patch | Prophylactic / vaccine patch | III | Efficacy data 2010 | GSK |
| 3 | S. aureus vaccine | Prophylactic | II/III (Sequential design) | Efficacy data 2010 Phase III start |
Merck & Co, Inc. |
| 4 | Pseudomonas vaccine | Prophylactic | II | Phase III start |
In-house |
| 5 | Hepatitis C Virus vaccine | Therapeutic | II | Define combination/ alliance |
Novartis |
| 6 | Pandemic Influenza vaccine patch | Prophylactic / vaccine patch | II | Phase II data early 2010 | GSK/ HHS |
| 7 | IC31® Seasonal Influenza vaccine | Prophylactic | I | Phase II start | Novartis |
| 8 | Tuberculosis vaccine | Prophylactic | I/II | Phase II start | SSI / sanofi-aventis |
| 9 | Pnemococcus vaccine | Prophylactic | I | Start of clinical trials in target populations (children/elderly) | In-house / PATH |
Vaccines in pre-clinical stages
| Product Candidate |
Vaccine Type |
Status/ Phase |
Expected Milestones |
Strategic Partner |
|
|---|---|---|---|---|---|
| 10 | Group A Streptococcus vaccine | Prophylactic | Pre-clinical | Phase I start | Merck & Co., Inc. |
| 11 | Bacterial vaccine (Undisclosed indication) | Prophylactic | Pre-clinical | Phase I start | sanofi-aventis |
| 12 | Lyme Borreliosis vaccine | Prophylactic | Pre-clinical | Phase I start | In-house |
Antibodies in development
| Product Candidate |
Antibody Type |
Status/ Phase |
Expected Milestones |
Strategic Partner |
|
|---|---|---|---|---|---|
| 13 | S. aureus antibodies | Antibodies (in infected patients) | Pre-clinical | Phase I start | Merck & Co., Inc. |
| 14 | Pneumococcus antibodies | Antibodies (in the elderly) | Pre-clinical | Phase I start | Kyowa Hakko Kirin |
| 15 | Group A Streptococcus antibodies | Antibodies (in infected patients) | Pre-clinical | Phase I start | In-house |
| 16 | Group B Streptococcus antibodies | Antibodies (in premature newborns) | Pre-clinical | Phase I start | In-house |